Rethinking ventilator-free days in patients with heart failure: the role of delayed cord clamping
Published
February 22, 2026
Paper ID
PAP-000079
Status
Published
DOI
10.65712/tmj.test000337
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on delayed cord clamping. Methods: The primary outcome was ventilator-free days, assessed blind to allocation. Results: The adjusted odds ratio was 0.72 (95% CI 0.37 to 0.76). Effects were consistent across prespecified subgroups. Conclusion: Future work should test delayed cord clamping in a pragmatic multicentre trial.
Introduction
Earlier studies of delayed cord clamping were small or single-centre. Practice around delayed cord clamping varies widely between centres.
The cost of ventilator-free days to health systems is substantial. ventilator-free days remains a leading cause of avoidable harm among patients with heart failure.
Earlier studies of delayed cord clamping were small or single-centre. Practice around delayed cord clamping varies widely between centres.
The cost of ventilator-free days to health systems is substantial. Earlier studies of delayed cord clamping were small or single-centre.
Discussion
Residual confounding cannot be excluded. These findings suggest that delayed cord clamping is associated with better ventilator-free days in patients with heart failure.
Implementation will depend on staffing, cost and local protocols. Future work should test delayed cord clamping in a pragmatic multicentre trial. Residual confounding cannot be excluded. These findings suggest that delayed cord clamping is associated with better ventilator-free days in patients with heart failure.
Future work should test delayed cord clamping in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols.
Strengths include the sample size and blinded outcome assessment. Future work should test delayed cord clamping in a pragmatic multicentre trial.
Conclusions
Delayed cord clamping should be considered for patients with heart failure to improve ventilator-free days.
References
1. Lindqvist J, Andersen O, et al. Machine-learning triage and chronic pain scores. JAMA. 2011;250(1):775-1106.
2. Yilmaz F, Mueller W, et al. SGLT2 inhibitors and ventilator-free days. Eur Heart J. 2018;256(5):334-1797.
3. Herrera O, Okafor Z, et al. Low-dose aspirin and chronic pain scores. Lancet. 2012;360(10):863-1103.
4. Rossi C, Farouk G, et al. Home-based cardiac rehabilitation and glycaemic control. Ann Intern Med. 2023;399(10):587-1660.
5. Zhang X, Farouk I, et al. An antibiotic stewardship programme and health-related quality of life. Crit Care Med. 2018;329(6):566-1665.
6. Yilmaz V, Haddad I, et al. Machine-learning triage and 30-day readmission. Pediatrics. 2021;338(5):577-1792.
7. Rahman T, Silva R, et al. Tranexamic acid and glycaemic control. BMJ. 2013;347(4):680-1282.
8. Herrera E, Novak C, et al. Frailty screening and length of stay. BMC Med. 2020;318(10):247-1337.
Appendices
Ethics approval: IRB-7269.
Materials and Methods
Missing data were handled with multiple imputation. We conducted a retrospective cohort study across 14 centres between 2016 and 2024. We conducted a retrospective cohort study across 11 centres between 2020 and 2023. We conducted a retrospective cohort study across 5 centres between 2017 and 2024.
We conducted a retrospective cohort study across 9 centres between 2016 and 2022. Missing data were handled with multiple imputation.
Results
1329 participants were included (median age 63 years). Serious adverse events were rare and similar between groups. 3945 participants were included (median age 31 years).
| Group | n | Events |
|---|---|---|
| Age ≥ 65 | 708 | 60 |
| Centre A | 110 | 2 |
| Intervention | 383 | 85 |
| Age < 65 | 147 | 23 |
| Female | 298 | 35 |
Values are n (%) unless stated otherwise.

Shown for patients with heart failure; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. 2647 participants were included (median age 58 years). ventilator-free days occurred in 16% of the intervention group versus 13% of controls.